Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice.

Clicks: 204
ID: 118734
1994
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #199 of 292 articles by views in Proceedings of the National Academy of Sciences of the United States of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 292 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Previously, recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fabs were generated by antigen selection from random combinatorial libraries displayed at the tip of filamentous phage. Two such Fabs, which exhibited high binding affinity ...
Reference Key
burton1994proceedingsrecombinant Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors J E Crowe, Jr, B R Murphy, R M Chanock, R A Williamson, C F Barbas, 3rd, D R Burton;J E Crowe, Jr;B R Murphy;R M Chanock;R A Williamson;C F Barbas, 3rd;D R Burton;
Journal Proceedings of the National Academy of Sciences of the United States of America
Year 1994
DOI
10.1073/pnas.91.4.1386
URL
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC43163/
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.